Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Pfizer Ltd - 500680 - Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Re-Appointment Of Independent Directors.

 Pursuant to regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company has re-appointed Mr. R. A. Shah (DIN: 00009851), Mr. Pradip Shah (DIN: 00066242) and Mr. Uday Khanna (DIN: 00079129) with effect from November 10, 2019 and Mr. Sunil Lalbhai (DIN: 00045590) with effect from February 14, 2020 as Independent Directors of the Company for a period of 5 years. The said re-appointments will be subject to the approval of shareholders at the ensuing Annual General Meeting of the Company. Enclosed are the brief profiles of the above Independent Directors:
29-05-2019
Bigul

Pfizer net profit climbs 17.23% to Rs 430.10 crore in FY19; board declares dividend of Rs 22.50 per share

 During the January-March quarter, Pfizer's net profit grew by 4.74 per cent to Rs 109.47 crore from Rs 104.5 1 crore in the same period last year
28-05-2019
Bigul

PFIZER LTD. - 500680 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Please find enclosed press release for the financial results for the quarter and financial year ended March 31, 2019. Please take the above on record.
28-05-2019
Bigul

PFIZER LTD. - 500680 - Board recommends Dividend

 Pfizer Ltd has informed BSE that the Board of Directors of the Company at its Meeting held on May 28, 2019, inter alia, has recommended a dividend of 225% (Rs. 22.50 per equity share of Rs. 10/- each) for the financial year ended March 31, 2019. The said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on August 26, 2019.
28-05-2019
Bigul

PFIZER LTD. - 500680 - Audited Financial Results And Audit Report For The Financial Year Ended March 31, 2019.

 Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith audited financial results for the financial year ended March 31, 2019, Statement of Assets and Liabilities as on March 31, 2019, Declaration with respect to Audit Report with unmodified opinion and the Auditor's Report by Auditors, M/s. Walker Chandiok & Co LLP, which were approved by the Board of Directors of the Company at its meeting held today, that commenced at 3.00 p.m. and concluded at 4.45 p.m. Further, please be informed that the Board of Directors of the Company has recommended a dividend of 225% (Rs. 22.50 per equity share of Rs. 10/- each) for the financial year ended March 31, 2019. The said dividend, if declared at the ensuing Annual General Meeting of the Company, shall be paid on August 26, 2019. We request you to kindly take the same on record.
28-05-2019
Bigul

Annual report for Pfizer Ltd. for FY-2019
28-05-2019
Bigul

PFIZER LTD. - 500680 - Board to consider FY19 results & Dividend on May 28, 2019

 Pfizer Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 28, 2019, inter alia, to consider and take on record the Audited Financial Results of the Company for the financial year ended March 31, 2019.At the said meeting, the Board of Directors will also consider recommendation of Dividend, if any, for the financial year ended March 31, 2019.Pursuant to the "Pfizer Limited - Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders', the Trading Window of the Company remains closed from Monday, April 1, 2019 till 48 hours after the results are made public on May 28, 2019.
17-05-2019
Bigul

PFIZER LTD. - 500680 - Board Meeting Intimation for Board Meeting For The Audited Financial Results For The Financial Year Ended March 31, 2019 And Closure Of Trading Window.

 PFIZER LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2019 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 28, 2019, inter alia, to consider and take on record the Audited Financial Results of the Company for the financial year ended March 31, 2019. At the said meeting, the Board of Directors will also consider recommendation of dividend,if any, for the financial year ended March 31, 2019. Pursuant to the "Pfizer Limited - Code of Internal Procedures and Conduct to Regulate, Monitor and Report Trading by Insiders', the Trading Window of the Company remains closed from Monday, April 1, 2019 till 48 hours after the results are made public on May 28, 2019. We request you to kindly take the same on record.
17-05-2019
Bigul

PFIZER LTD. - 500680 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayPFIZER LTD. 2CININE182A01018 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRAJEET NAIR Designation: COMPANY SECRETARY EmailId: prajeet.nair@pfizer.com Name of the Chief Financial Officer: MILIND PATIL Designation: CHIEF FINANCIAL OFFICER EmailId: milind.anil.patil@pfizer.com Date: 30/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
30-04-2019
Bigul

Local pharma companies to challenge MNCs in pneumonia vaccine space

 The Indian market is at present dominated by GlaxoSmithKline Pharma and Pfizer
20-04-2019
Next Page
Close

Let's Open Free Demat Account